Author

Yolande Jefferson

Observed names: Jefferson, Yolande, Yolande Jefferson-Hulme

Institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

Observed institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

ORCID: 0009-0000-2549-5538

Observed ORCID: 0009-0000-2549-5538

OpenAlex ID: A5081996423

PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial

2024 · Paul Nankivell, Piers Gaunt, et al. · BMC Cancer · 11

The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.

2017 · Peter Hillmen, Andy C. Rawstron, et al. · Haematologica · 5

Rational treatment selection for primary Merkel Cell Carcinoma: a Rational MCC RCT comparing surgery and radiotherapy with parallel observational study

2025 · Neil M Steven, Sarah Pirrie, et al. · Efficacy and Mechanism Evaluation · 1

Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial

2024 · Paul Nankivell, Piers Gaunt, et al. · BMC Cancer · 1

The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy

2017 · S Munoz-Vicente, R Bishop, et al. · Leukemia & lymphoma/Leukemia and lymphoma

Works count: 11

Citation count: 18

H-index: 2

I10-index: 1